Replies to post #471018 on NorthWest Biotherapeutics Inc (NWBO)

[highwayman4life]

Well Ex, you must know better than all of the actual medical experts in the field b/c apparently to them, the TLD from the DCVaxL trial is a "big win for the brain tumor patient community."

I know nothing about how the stock market works. Especially after yesterday. I used to think good news send stock prices up. But I do know a LOT about brain tumors and we should be focusing on this as a big win for the brain tumor patient community.

— Al Musella (@AlMusella) May 11, 2022

GLTA

[hoffmann6383]

I'll trust the experts over a shareholder that touted fabricated checkmate data to attempt to put NWBO in a bad light, falsely insinuated Bigger and insiders were selling in an attempt to induce panic, pushed far flung criminal conspiracy theories and just 24 hours ago was claiming no TLD was being released at the NYAS

Have a good one Ex. By.

[j e d]

how do you not get this? the control group was artificially strengthened because the weakest controls crossed over. by the end of the trial, only the controls that did not progress remained as controls. this is in essence cherry-picking the most resilient people to comprise the control group. and this is why that endpoint was found unviable, and why comparing blended to unblinded makes no sense.

by the end of the trial, any “controls” left were only those who are naturally hyper-resilient and lucky. this is no longer a control group.

a typical placebo patient would NOT experience what the remaining “controls” in this trial experienced. this is the whole reason for the endpoint change and ECA.

i’m redundant here but i’m not sure how else to explain it to you. usually you don’t go out of your way to lie but you keep hammering this point as if you don’t get it

[flipper44]

I stand corrected on the Ltfu.

But Ex, that would mean out of 231 nGBM, there were only 5 lost to follow up over a 14 year trial.

And that would mean in the rGBM group, there were none lost to follow up at 24 months past recurrence.